Free Trial
NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Iterum Therapeutics logo
$0.93 +0.02 (+1.65%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.94 +0.01 (+1.17%)
As of 05/22/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Key Stats

Today's Range
$0.89
$0.94
50-Day Range
$0.92
$1.45
52-Week Range
$0.81
$3.02
Volume
561,340 shs
Average Volume
1.03 million shs
Market Capitalization
$37.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

ITRM MarketRank™: 

Iterum Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 589th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Iterum Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Iterum Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iterum Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iterum Therapeutics is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    2.75% of the float of Iterum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iterum Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Iterum Therapeutics has recently decreased by 16.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Iterum Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Iterum Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.75% of the float of Iterum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iterum Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Iterum Therapeutics has recently decreased by 16.13%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Iterum Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for ITRM on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Iterum Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

  • Read more about Iterum Therapeutics' insider trading history.
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Stock News Headlines

Washington Is Broke—and Eyeing Your Savings Next
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
Brokers Set Expectations for ITRM Q1 Earnings
See More Headlines

ITRM Stock Analysis - Frequently Asked Questions

Iterum Therapeutics' stock was trading at $1.77 at the start of the year. Since then, ITRM stock has decreased by 47.4% and is now trading at $0.9311.
View the best growth stocks for 2025 here
.

Iterum Therapeutics plc (NASDAQ:ITRM) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14).
Read the conference call transcript
.

Iterum Therapeutics shares reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Iterum Therapeutics' top institutional shareholders include OneDigital Investment Advisors LLC (0.29%). Insiders that own company stock include Michael W Dunne, Corey N Fishman, Brenton Karl Ahrens and Sailaja Puttagunta.
View institutional ownership trends
.

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Video Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Therapeutics (ATOS).

Company Calendar

Last Earnings
5/13/2025
Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+886.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-7.60

Miscellaneous

Free Float
31,400,000
Market Cap
$36.48 million
Optionable
Not Optionable
Beta
2.91
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ITRM) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners